Research Library
TIRZ / IGF-1 LR3 research
6 articles to explore, with links to 11 original sources.
About TIRZ / IGF-1 LR3
This blend combines TIRZ and IGF-1 LR3 in the listed Heritage amounts for laboratory research.
Explore study findings
What a myostatin antibody study tells us about its own target
Tirzepatide is a peptide that activates the GIP and GLP-1 receptors. IGF-1 LR3 is an engineered, extended insulin-like growth factor protein. A 2026 trial added a different molecule to tirzepatide, the antibody apitegromab.
3 sources (1992, 2026)
Check methods and identity
Why two compounds given together and a single formulation are separate questions
Tirzepatide is a GIP and GLP-1 receptor agonist peptide. IGF-1 LR3 is a modified version of the growth-factor protein IGF-1. Studies registered for tirzepatide with a different molecule illustrate why the preparation is part of what researchers have to define.
3 sources (2023–2026)
How an assay separates intact IGF-1 LR3 from its breakdown products
Tirzepatide is a peptide that activates GIP and GLP-1 receptors, while IGF-1 LR3 is an engineered growth-factor protein. Older research developed a way to distinguish the intact growth-factor analog from related molecules and some of its breakdown products.
2 sources (2021, 2026)
Why studies measure food intake separately from body weight
Tirzepatide activates GIP and GLP-1 receptors. IGF-1 LR3 is an engineered, extended version of insulin-like growth factor 1. Older direct experiments on each component help explain why a study of the pair would need to measure food intake separately from weight and tissue outcomes.
2 sources (1997, 2025)
Interpret the evidence
What basal insulin studies tell us about the limits of an add-on result
Tirzepatide activates GIP and GLP-1 receptors. IGF-1 LR3 is a modified insulin-like growth factor protein. A 2026 analysis examined tirzepatide added to basal insulin and shows why an add-on result has to be read with the exact background treatment in view.
3 sources (2023, 2026)
What a digestion experiment can tell us about an IGF-1 LR3 variant
Tirzepatide is a GIP and GLP-1 receptor agonist peptide. IGF-1 LR3 is a modified, extended growth-factor protein. An older study investigated which changes to LR3 made the resulting molecules more resistant to a digestive enzyme. The researchers tested purified pepsin from pigs in the laboratory.
2 sources (1996, 2026)
